[1] L. Bergman, B. Nilsson, G. Lundell, M. Lundell and S. Seregard. Ruthenium Brachytherapy for Uveal Melanoma, 1979–2003, Ophthalmology, 112(5) (2005) 834–840.
[2] N. Kaiserman, I. Kaiserman, K. Hendler, S. Frenkel and J. Pe’er. Ruthenium-106 plaque brachytherapy for thick posterior uveal melanomas, British Journal of Ophthalmology, 93(9) (2009) 1167–1171.
[3] K. M. Verschueren, C.L. Creutzberg, N.E. Schalij-Delfos, M. Ketelaars, F.L. Klijsen, B.I. Haeseker, S.M. Ligtenberg, J.E. Keunen and C.A. Marijnen. Long-term outcomes of eye-conserving treatment with Ruthenium-106 brachytherapy for choroidal melanoma, Radiotherapy and Oncology, 95(3) (2010) 332–338.
[4] A.O. Schueler, D. Flühs, G. Anastassiou, C. Jurklies, M. Neuhäuser, H. Schilling, N. Bornfeld and W. Sauerwein. Beta-ray brachyterapy with 106Ru plaques for Retinoblastoma, International Journal of Radiation Oncology • Biology • Physics, 65(4) (2006) 1212–1221.
[5] E.R. Simpson, B. Gallie, N. Laperrierre, A. Beiki-Ardakani, T. Kivelä, V. Raivio, J. Heikkonen, L. Desjardins, R. Dendale, A. Mazal, N. Bornfeld, W. Sauerwein, D. Flüehs, L. Brualla, S.G. Honavar, V.A. Reddy, S. Suzuki, N. Murakami, S. Saakyan, V. Valskiy, A. Amiryan, S. Seregard, C. All-Eriksson, L. Hjelmqvist, G. Lundell, G. Sinclair, M. Lundell, B. Damato, R.D. Errington, P. Mayles, H. Mayles, C. Bergstrom, H. Grossniklaus, I. Crocker, E. Butker, M. Wilson, B. Haik, H. Geischen, P. Patra, J. Duker, J. Mignano, M. Rivard, P.T. Finger, E. Semenova, W. Choi and N.I. Kalach. The American Brachytherapy Society consensus guidelines for plaque brachytherapy of uveal melanoma and retinoblastoma. Brachytherapy, 13(1) (2014) 1–14.
[6] R.V. Ginderdeuren, E.V. Limbergen and W. Spileers. 18 Years’ experience with high dose rate strontium-90 brachytherapy of small to medium sized posterior uveal melanoma, British Journal of Ophthalmology, 89(10) (2005) 1306–1310.
[7] S. Laskar, L. Gurram, G. Laskar, S. Chaudhari, N. Khanna and R. Upreti. Superficial ocular malignancies treated with strontium-90 brachytherapy: long term outcomes. Contemporary Brachytherapy, 7(5) (2015) 369–372.
[8] V.M. Cohen, V.P. Papastefanou, S. Liu, I. Stoker and J.L. Hungerford. The Use of Strontium-90 Beta Radiotherapy as Adjuvant Treatment for Conjunctival Melanoma, Journal of Oncology, (11) (2013) 1–7.
[9] M.F. L’Annunziata. Handbook of Radioactivity Analysis, table of Radioactive Isotopes, (2012) 1305–1360.
[10] S. Agostinelliae, J. Allisonas, K. Amakoe, J. Apos, H. Araujoaj, P. Arcel, M. Asaig, D. Axeni, S. Banerjeebi, G. Barrandan, F. Behnerl, L. Bellag, J. Boudreaubd, L. Brogliaar, A. Brunengoc, H. Burk, S. Chauviebj, J. Chumah, R. Chytraceka, G. Cooperm, G. Cosmoa, P. Degtyarenkod, A. Dell’Acquaa, G. Dep, D. Dietrichaf, R. Enamiab, A. Feliciellobj, C. Fer, H. Fesefeldtl, G. Folgera, F. Foppianoac, A. Forti, S. Garelliac, S. Giania, R. Giannitrapanibo, D. Gi and et al. Geant4—a simulation toolkit, Nuclear Instruments and Methods in Physics Research A, 506 (2003) 250–303.
[11] S. Devic, N. Tomic and D. Lewis. Reference radiochromic film dosimetry: Review of technical aspects, Physica Medica, 32(4) (2016) 541–556.
)